Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 7/20 | 0.59 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.54 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.50 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.50 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31554630 | 1.00 | CRBN (0.59) | CRBNGPR119IKZF2CSNK1A1DDB1 | |
| SCHEMBL20234406 | 0.93 | CRBN (0.62) | CRBNGPR119IKZF2CSNK1A1DDB1 | |
| SCHEMBL21753199 | 0.93 | CRBN (0.59) | CRBNGPR119IKZF2CSNK1A1DDB1 | |
| SCHEMBL32660167 | 0.93 | CRBN (0.59) | CRBNGPR119IKZF2CSNK1A1DDB1 | |
| SCHEMBL20442568 | 0.91 | GPR119 (0.67) | CRBNGPR119IKZF2CSNK1A1DDB1 | |
| SCHEMBL28881307 | 0.88 | CRBN (0.59) | CRBNIKZF2CSNK1A1DDB1GSPT1 | |
| SCHEMBL20231775 | 0.88 | IKZF2 (0.59) | CRBNIKZF2CSNK1A1DDB1GSPT1 | |
| SCHEMBL20231483 | 0.86 | CRBN (0.53) | CRBNGPR119IKZF2CSNK1A1DDB1 | |
| SCHEMBL22848677 | 0.86 | CRBN (0.68) | CRBNGPR119DDB1GSPT1 | |
| SCHEMBL30906228 | 0.86 | CRBN (0.53) | CRBNGPR119IKZF2CSNK1A1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736882-A2 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-3841098-B1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-12-25 | — | — | US | disclosed |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2025-09-09 | — | — | US | disclosed |
| US-20240400570-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2024-12-05 | — | — | US | disclosed |
| US-12065442-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2024-08-20 | — | — | US | disclosed |
| US-11969472-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2024-04-30 | — | — | US | disclosed |
| CN-115626927-B | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| CN-115697989-A | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115626927-A | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-01-20 | — | — | CN | disclosed |
| EP-4110772-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2023-01-04 | — | — | EP | disclosed |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-11-25 | — | — | US | disclosed |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-10-14 | — | — | US | disclosed |
| EP-3841098-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2021-06-30 | — | — | EP | disclosed |
| CN-112888681-A | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2021-06-01 | — | — | CN | disclosed |
| WO-2020038415-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CRBN 330/4885GPR119 2952/4885IKZF2 2170/4885 |
| US-11969472-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, ERBB2, NTRK1 | CRBN 330/4885GPR119 2952/4885IKZF2 2170/4885 |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, ERBB2, NTRK1 | CRBN 330/4885GPR119 2952/4885IKZF2 2170/4885 |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | ERBB2, MUSK, ERBB3 | CRBN 149/4885GPR119 2064/4885IKZF2 2290/4885 |
| US-20240400570-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CRBN 330/4885GPR119 2952/4885IKZF2 2170/4885 |
| US-12065442-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, NTRK1, ERBB2 | CRBN 194/4885GPR119 2986/4885IKZF2 1536/4885 |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, NTRK1, ERBB2 | CRBN 194/4885GPR119 2986/4885IKZF2 1536/4885 |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CRBN 330/4885GPR119 2952/4885IKZF2 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.